RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer 19 Jan, 2023 | 13:41h | UTC Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 – Journal of Clinical Oncology Commentary: First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer – The ASCO Post